SOURCE: NICOX

June 23, 2006 05:14 ET

NicOx to Present at the Jefferies Life Sciences conference

Sophia Antipolis Cedex -- (MARKET WIRE) -- June 23, 2006 -- June 23, 2006. Sophia Antipolis, France. www.nicox.com

NicOx S.A. (Eurolist: NICOX) today announced that it will present at the Jefferies Life Sciences conference on Wednesday June 28, 2006 at 8:00 am US Eastern Time (1:00 pm UK - 2:00 pm CET) at the Mandarin Oriental in New York, USA.

Michele Garufi, Chairman and Chief Executive Officer of NicOx, will provide an update on the Company's corporate and development progress.

To access the audio broadcast or the subsequent archived recording log onto http://www.nicox.com. Please connect to the website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide-donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of pain and inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 development for the treatment of osteoarthritis, and NCX 4016, in phase 2 for Peripheral Arterial Obstructive Disease (PAOD). NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck and Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext Paris (segment: Next Economy).

The elements included in this communication may contain forward looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risks factors described in the company's document de reference.

CONTACTS:

NicOx: Karl Hanks - Manager of Corporate Relations and Market Analysis - Tel +33 (0)4 97 15 22 03 - hanks@nicox.com - www.nicox.com

Investors in the United States - Burns McClellan: Lisa Burns - lburns@burnsmc.com / Laura Siino - lsiino@burnsmc.com - Tel +1 212 213 0006

Financial Dynamics: Jonathan Birt - Tel +1 212 850 56 34 - jbirt@fd-us.com / Julia Phillips - Tel +44 (0)20 7831 3113 - julia.phillips@fd.com

This information is provided by CompanynewsGroup

Contact Information